Rheumatoid arthritis product development draft guidance available from FDA; public workshop announced.
Executive Summary
RHEUMATOID ARTHRITIS PRODUCT DRAFT GUIDANCE POSES SIX-MONTH DATA REQUIREMENT for remission claims. The draft, published in the March 6 Federal Register, proposes that RA remission claims be based on a "statistically significant improvement in remission rate, sustained over six months, that is at least 20% higher in absolute value than the observed rate in control patients treated with current standard therapies appropriate for their stage and severity of disease."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth